Fifth Third Bancorp Sells 68,010 Shares of Haleon plc (NYSE:HLN)

Fifth Third Bancorp lowered its position in Haleon plc (NYSE:HLN) by 18.3% in the 4th quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 303,549 shares of the company’s stock after selling 68,010 shares during the period. Fifth Third Bancorp’s holdings in Haleon were worth $2,896,000 as of its most recent SEC filing.

Several other hedge funds also recently made changes to their positions in HLN. Fortitude Family Office LLC purchased a new position in Haleon during the third quarter valued at $28,000. Versant Capital Management Inc raised its position in shares of Haleon by 2,029.1% in the 4th quarter. Versant Capital Management Inc now owns 3,513 shares of the company’s stock worth $34,000 after purchasing an additional 3,348 shares during the last quarter. Toronto Dominion Bank boosted its stake in Haleon by 3,470.0% in the 3rd quarter. Toronto Dominion Bank now owns 3,570 shares of the company’s stock worth $38,000 after purchasing an additional 3,470 shares in the last quarter. Prospera Private Wealth LLC purchased a new stake in Haleon during the 3rd quarter valued at about $57,000. Finally, Brooklyn Investment Group increased its stake in Haleon by 168.1% during the 4th quarter. Brooklyn Investment Group now owns 6,080 shares of the company’s stock valued at $58,000 after purchasing an additional 3,812 shares in the last quarter. 6.67% of the stock is currently owned by institutional investors.

Haleon Trading Up 2.1 %

NYSE:HLN opened at $9.59 on Tuesday. The company has a 50 day simple moving average of $9.54 and a two-hundred day simple moving average of $9.74. The company has a market cap of $43.39 billion, a PE ratio of 28.19, a price-to-earnings-growth ratio of 2.60 and a beta of 0.29. The company has a current ratio of 0.84, a quick ratio of 0.58 and a debt-to-equity ratio of 0.44. Haleon plc has a 12 month low of $7.89 and a 12 month high of $10.80.

Haleon (NYSE:HLN) last posted its quarterly earnings data on Thursday, October 31st. The company reported $0.14 EPS for the quarter, beating analysts’ consensus estimates of $0.11 by $0.03. The company had revenue of $3.62 billion during the quarter, compared to analysts’ expectations of $3.74 billion. Haleon had a return on equity of 14.76% and a net margin of 10.85%. During the same quarter in the prior year, the business earned $0.10 earnings per share. Research analysts forecast that Haleon plc will post 0.44 earnings per share for the current year.

Analyst Ratings Changes

A number of brokerages recently weighed in on HLN. UBS Group upgraded shares of Haleon to a “strong-buy” rating in a report on Tuesday, October 1st. Sanford C. Bernstein downgraded Haleon from an “outperform” rating to a “market perform” rating in a report on Wednesday, January 8th. Finally, Morgan Stanley downgraded Haleon from an “overweight” rating to an “equal weight” rating in a report on Friday, January 10th. Three equities research analysts have rated the stock with a hold rating, three have assigned a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $10.95.

Haleon Company Profile

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.